The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Combo of RG6146/venetoclax/rituximab for R/R DLBCL: initial data
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the combination of the BET inhibitor RG6146, venetoclax and rituximab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). He reports the initial Phase Ib safety, biomarker and response data (NCT03255096). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
